Mar 31, 2022

Penumbra Q1 2022 Earnings Report

Penumbra reported revenue increase of 20.5% compared to the first quarter of 2021.

Key Takeaways

Penumbra, Inc. reported financial results for the first quarter ended March 31, 2022, with revenue of $203.9 million, an increase of 20.5% compared to the first quarter of 2021.

Total revenue increased to $203.9 million for the first quarter of 2022 compared to $169.2 million for the first quarter of 2021, an increase of 20.5%.

Revenue from sales of vascular products grew to $122.8 million for the first quarter of 2022, an increase of 37.7%.

Revenue from sales of neuro products grew to $81.1 million for the first quarter of 2022, an increase of 1.3%.

Gross profit was $127.4 million, or 62.5% of total revenue for the first quarter of 2022.

Total Revenue
$204M
Previous year: $169M
+20.5%
EPS
-$0.01
Previous year: $0.27
-103.7%
Gross Margin
62.5%
Previous year: 65.8%
-5.0%
Gross Profit
$127M
Previous year: $111M
+14.4%
Cash and Equivalents
$68.2M
Previous year: $55.6M
+22.5%
Total Assets
$1.3B
Previous year: $841M
+54.8%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

No forward guidance was provided in the earnings report.

Revenue & Expenses

Visualization of income flow from segment revenue to net income